The aim of this study was to compare the effects of cisapride and tegaserod on intestinal smooth muscle activity in equines. Efficacy was evaluated through measurement of gastrointestinal transit time, bowel movements per day, stool weight, and bowel sounds. Drug safety was evaluated via heart rate, respiratory rate, and rectal temperature. Records were obtained throughout three periods: a control phase without treatment, a period of cisapride administration at a dose of 0.22 mg/kg, and a period of tegaserod treatment at a dose of 0.27 mg/kg. Gastrointestinal transit time, bowel movements per day, and stool weight were significantly improved on administration of both cisapride and tegaserod, as compared with the control phase. With tegaserod administration, gastrointestinal transit time accelerates more than to cisapride administration; however, no significant difference was seen in bowel movements per day and stool weight. In terms of heart rate, respiratory rate, and rectal temperature, no significant variations were seen between the three sample phases. Because of the above findings, tegaserod can be considered an effective stimulant of intestinal smooth muscle, accelerating gastrointestinal transit time in healthy horses and representing a potential therapeutic agent similar to cisapride.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jevs.2020.103179 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gene therapy ameliorates bowel dysmotility and enteric neuron degeneration and extends survival in lysosomal storage disorder mouse models.
Sci Transl Med
January 2025
Department of Pediatrics, Washington University in St. Louis, School of Medicine, St. Louis, MO 63110, USA.
Children with neurodegenerative disease often have debilitating gastrointestinal symptoms. We hypothesized that this may be due at least in part to underappreciated degeneration of neurons in the enteric nervous system (ENS), the master regulator of bowel function. To test this hypothesis, we evaluated mouse models of neuronal ceroid lipofuscinosis type 1 and 2 (CLN1 and CLN2 disease, respectively), neurodegenerative lysosomal storage disorders caused by deficiencies in palmitoyl protein thioesterase-1 and tripeptidyl peptidase-1, respectively.
View Article and Find Full Text PDFAdvanced polymeric systems for colon drug delivery: from experimental models to market applications.
Soft Matter
January 2025
Department of Chemical Materials and Industrial Production (DICMaPI), University of Naples Federico II, P.le Tecchio 80, Naples 80125, Italy.
In recent years, nano and micro drug delivery systems targeting the colon have gained more attention due to increasing interest in treating colon diseases such as colorectal cancer and inflammatory bowel disease, , Crohn's disease and ulcerative colitis. Usually, nanocarriers are exploited for their enhanced permeability properties, allowing higher penetration effects and bioavailability, while microcarriers are primarily used for localized and sustained release. In bowel diseases, carriers must go into a delicate environment with a strict balance of gut bacteria (, colon), and natural or biodegradable polymers capable of ensuring lower toxicity are preferred.
View Article and Find Full Text PDFPolysaccharide-based drug delivery targeted approach for colon cancer treatment: A comprehensive review.
Int J Biol Macromol
January 2025
Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address:
Colon cancer is a leading cause of cancer-related morbidity and mortality worldwide, necessitating advancements in therapeutic strategies to improve outcomes. Current treatment modalities, including surgery, chemotherapy, and radiation, are limited by systemic toxicity, low drug utilization rates, and off-target effects. Colon-targeted drug delivery systems (CDDS) offer a promising alternative by leveraging the colon's unique physiology, such as near-neutral pH and extended transit time, to achieve localized and controlled drug release.
View Article and Find Full Text PDFAssociation of Mucin-Degrading Gut Microbiota and Dietary Patterns with Colonic Transit Time in Constipation: A Secondary Analysis of a Randomized Clinical Trial.
Nutrients
December 2024
Department of Bioconvergence, Hoseo University, 165 Sechul-Ri, BaeBang-Yup, Asan 31499, ChungNam-do, Republic of Korea.
Background: The relationship between gut microbiota composition, lifestyles, and colonic transit time (CTT) remains poorly understood. This study investigated associations among gut microbiota profiles, diet, lifestyles, and CTT in individuals with subjective constipation.
Methods: We conducted a secondary analysis of data from our randomized clinical trial, examining gut microbiota composition, CTT, and dietary intake in baseline and final assessments of 94 participants with subjective constipation.
Feasibility and complications of videocapsule endoscopy in dogs weighing 7 kg or less.
J Vet Intern Med
January 2025
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Background: Videocapsule endoscopy (VCE) is a valuable tool for investigating gastrointestinal (GI) diseases in dogs. Its use is not recommended in dogs ≤4.3 kg, because of risks of GI endoscopic capsule (EC) retention and bowel obstruction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!